Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Thais E.T. Pompeu"'
Autor:
Rafaela R. Silva, Lucas T. Parreiras-e-Silva, Thais E.T. Pompeu, Diego A. Duarte, Carlos A.M. Fraga, Eliezer J. Barreiro, Ricardo Menegatti, Claudio M. Costa-Neto, François Noël
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
LASSBio-579, an N-phenylpiperazine antipsychotic lead compound, has been previously reported as a D2 receptor (D2R) ligand with antipsychotic-like activities in rodent models of schizophrenia. In order to better understand the molecular mechanism of
Externí odkaz:
https://doaj.org/article/f45cf0135861424db33630b83e2d0e5f
Autor:
Lucas T. Parreiras-e-Silva, Thais E.T. Pompeu, Eliezer J. Barreiro, François Noël, Carlos A. M. Fraga, Diego A. Duarte, Rafaela R. Silva, Ricardo Menegatti, Claudio M. Costa-Neto
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
LASSBio-579, an N-phenylpiperazine antipsychotic lead compound, has been previously reported as a D2 receptor (D2R) ligand with antipsychotic-like activities in rodent models of schizophrenia. In order to better understand the molecular mechanism of
Autor:
Thais E.T. Pompeu, Barbara Bosier, François Noël, Emmanuel Hermans, Carlos A. M. Fraga, Fernando M. do Monte, Ricardo Menegatti, Eliezer J. Barreiro
Publikováno v:
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 62:1-6
In an attempt to better understand the molecular mechanism of action of the antipsychotic lead LASSBio-579 and of its main metabolite LQFM 037, the aim of this work was to evaluate their intrinsic activity and binding kinetics at the dopamine D2 rece
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 70:12-18
Introduction Determination of the intrinsic efficacy of ligands at the 5-HT 1A receptor is important for selecting drug candidates, e.g. in the case of schizophrenia where partial agonism is a favorable property shared by different atypical antipsych
Autor:
Teresa Dalla Costa, Camila B. Antonio, Tatiana F. Gomes, Thais E.T. Pompeu, Eric de Souza Gil, Stela Maris Kuze Rates, Carlos A. M. Fraga, Carolina Horta Andrade, José R. Sabino, Eliezer J. Barreiro, Ricardo Menegatti, Andresa Heemann Betti, Daniel Alencar Rodrigues, François Noël, Valéria de Oliveira
Publikováno v:
European Journal of Medicinal Chemistry. 62:214-221
Using a combination of docking and molecular dynamics simulations, we predicted that p-hydroxylation by CYP1A2 would be the main metabolic pathway for the 1-[1-(4-chlorophenyl)-1H-4pyrazolylmethyl] phenylhexahydropiperazine, LASSBio-579 (3). As the r
Autor:
Thais E.T. Pompeu, Camila B. Antonio, Carlos A. M. Fraga, Eliezer J. Barreiro, Vivian Herzfeldt, Thaise S. Martins, Eveline Dischkaln Stolz, Andresa Heemann Betti, Stela Maris Kuze Rates, François Noël
Publikováno v:
Behavioural pharmacology. 28(1)
Aiming to identify new antipsychotic lead-compounds, our group has been working on the design and synthesis of new N-phenylpiperazine derivatives. Here, we characterized LASSBio-1422 as a pharmacological prototype of this chemical series. Adult male
Autor:
Eliezer J. Barreiro, Carolina D.M. Figueiredo, Carlos A. M. Fraga, Stela Maris Kuze Rates, Fernando Rodrigues de Sa Alves, Camila B. Antonio, François Noël, Vivian Herzfeldt, Bruna C. Moura, Thais E.T. Pompeu
Publikováno v:
European journal of medicinal chemistry. 66
In an attempt to increase the affinity of our antipsychotic lead compound LASSBio-579 (1-((1-(4-chlorophenyl)-1H-pyrazol-4-yl)methyl)-4-phenylpiperazine; ( 2 )) for the 5-HT 2A receptor, we synthesized five new N -phenylpiperazine derivatives using a
Autor:
Silva, Rafaela R., Parreiras-e-Silva, Lucas T., Pompeu, Thais E.T., Duarte, Diego A., Fraga, Carlos A.M., Barreiro, Eliezer J., Menegatti, Ricardo, Costa-Neto, Claudio M., Noël, François
Publikováno v:
Frontiers in Pharmacology; 6/4/2019, pN.PAG-N.PAG, 10p